Metabolon is further expanding its international reach with a new lab in China.

The privately held, venture capital backed firm is partnering with Shanghaiu Jaio Tong University for the facility that will be located in Shanghai.

Financial terms were not disclosed.

Metabolon’s technology is based on metabolomics, the analysis of biochemicals such as sugars, nucleotides, fatty acids, amino acids and other small molecules, the company said. The biochemicals are analyzed in patient samples before being compared to other profiles.

Metabolon believes the data can be used for development of diagnostic tests as well as drug development and in monitoring for clinical trials. The company owns 17 patents.

The university is funding the lab and the hiring of personnel, who were trained by Metabolon.

“We are very pleased to be bringing the science of metabolomics to a large untapped market such as China and the Asian continent as a whole,” said Metabolon Chief Executive Officer John Ryals. “Our partnership with Shanghai Jiao Tong University is further proof of Metabolon’s efforts to bring personalized medicine and metabolic biomarker research to all parts of the globe.”
Metabolon also has offices in London and Madrid.

The company closed on $13.1 million in new venture funding in August. Its local investor is The Aurora Funds.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.